Clinical trials: Penile Diseases
Erectile Dysfunction, Impotence
PROPPER Prospective Registry of Outcomes With Penile Prosthesis
The purpose of this observational registry is to collect and better understand "real-world" outcomes for men undergoing penile implant surgery to treat erectile dysfunction.
- Trial name
- PROPPER (NCT01383018)
- Testing
- AMS Penile Prosthesis Devices
- Where
- 11 sites in United States, Canada
- Volunteers
- 1,457 people
- Sponsor
- Boston Scientific Corporation
Peyronie's Disease
Study of AA4500 in the Treatment of Peyronie's Disease
This study is a Phase 3, double-blind, randomized, placebo-controlled study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Approximately 400 (267 AA4500 and 133 placebo) men will be randomized.
- Trial name
- NCT01221597
- Testing
- AA4500
- Where
- 34 sites in United States, Australia
- Volunteers
- 418 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Erectile Dysfunction
Evaluation of the 2005 AMS (American Medical System) IPP (Inflatable Penile Prosthesis)
The purpose of this study is to evaluate modifications to the AMS 700 Series pump, cylinders, reservoir and rear tip extender design, their impact on ease of use for the patient, and ease of implantation for the physician.
- Trial name
- NCT00636506
- Testing
- AMS 700 IPP with MS Pump
- Where
- 7 sites in United States
- Volunteers
- 76 people
- Sponsor
- American Medical Systems
Sickle Cell Disease
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
The purpose of this study was to determine whether the investigational drug SelG1 when given to sickle cell disease patients either taking or not taking hydroxyurea was effective in preventing or reducing the occurrence of pain…
- Trial name
- SUSTAIN (NCT01895361)
- Testing
- SelG1
- Where
- 56 sites in United States, Brazil and 1 more
- Volunteers
- 198 people
- Sponsor
- Reprixys Pharmaceutical Corporation
Erectile Dysfunction
Evaluation of the Coloplast Titan® IPP for Maintaining Penile Length While Treating Erectile Dysfunction (ED)
This study is designed to assess the effectiveness of the Coloplast Titan® Inflatable Penile Prosthesis (IPP) at maintaining or increasing penile length after implantation of the device.
- Trial name
- NCT00731666
- Testing
- Inflatable Penile Prosthesis
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Coloplast A/S
Peyronie's Disease
A Study of AA4500 in Men With Peyronie's Disease
This study is a Phase 3, open-label study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Subjects will be screened for study eligibility within 21 days before the initial injection of study drug…
- Trial name
- NCT01243411
- Testing
- AA4500
- Where
- 39 sites in United States, Denmark and 7 more
- Volunteers
- 348 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Pain, Neuropathic, Epilepsy
Cancer in Patients With Gabapentin (GPRD)
High doses of gabapentin are associated with pancreatic acinar cell tumors in rats, but there has been no post marketing pancreatic carcinogenicity signal with gabapentin as reported by spontaneous reports in AERS or in the…
- Conditions
- Pain, Neuropathic, Epilepsy, Renal Pelvis Cancer, Pancreatic Cancer
- Trial name
- NCT01236053
- Testing
- Gabapentin prescriptions
- Volunteers
- 2,323,608 people
- Sponsor
- GlaxoSmithKline
Peyronie's Disease
The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease
This study evaluated the safety and effectiveness of AA4500 in improving the impact of Peyronie's disease on quality of life and improving penile curvature in men with Peyronie's disease
- Trial name
- NCT00755222
- Testing
- AA4500
- Where
- 12 sites in United States
- Volunteers
- 147 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Erectile Dysfunction
Titan® One Touch Release Inflatable Penile Prosthesis
The purpose of this study is to assess the ease of deflation of the Titan® OTR pump.
- Trial name
- NCT00731939
- Testing
- Inflatable Penile Prosthesis
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 124 people
- Sponsor
- Coloplast A/S
Priapism
A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism
The goal of the study was to evaluate the efficacy and safety of crizanlizumab in sickle cell disease (SCD) patients with priapism.
- Trial name
- SPARTAN (NCT03938454)
- Testing
- Crizanlizumab
- Where
- 13 sites in United States
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Peyronie's Disease
Study of AA4500 in the Treatment of Peyronie's Disease
This study is a Phase 3, double-blind, randomized, placebo-controlled study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Approximately 300 (200 AA4500 and 100 placebo) men will be randomized.
- Trial name
- NCT01221623
- Testing
- AA4500
- Where
- 34 sites in United States, Australia
- Volunteers
- 418 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Peyronie's Disease
A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease
This study is a Phase 3, open-label study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Subjects will be screened for study eligibility within 21 days before the initial injection of study drug…
- Trial name
- NCT01685437
- Testing
- AA4500
- Volunteers
- 189 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Peyronie's Disease
Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease
This study is a Phase 2, open-label study to assess the pharmacokinetics (PK) and safety of AA4500 0.58 mg in men with Peyronie's disease.
- Trial name
- NCT01430169
- Testing
- AA4500
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company